Targazyme
Reid Bissonnette is an experienced professional in the field of Immuno-Oncology, Oncology, and Immunology. Currently serving as a Consultant at Xenetic Biosciences, Inc. and Radionetics Oncology, as well as holding advisory roles at Circulants and Demigos. Previously, Reid held the position of Vice President of Immuno-Oncology at TargaZyme, Inc. with a background in Pharmacology and Oncology Drug Discovery and Development. With a PhD in Tumor Immunology and Cellular Immunology from McGill University, Reid's expertise is highly valuable in the pharmaceutical industry.
Targazyme
Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine.